8 unchanged sentences
Based on this assessment, management concluded that our internal control over financial reporting was effective as of December 31, 2024.
−Removed: This Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm on our internal control over financial reporting due to an exemption established by the JOBS Act for “emerging growth companies.”
+Added: Attestation Report of the Registered Public Accounting Firm
+Added: The effectiveness of our internal control over financial reporting has been audited by KPMG LLP, an independent registered public accounting firm, as stated in their attestation regarding internal controls over financial reporting included in the report of independent registered public accounting firm included in Item 8 of this Annual Report.
Changes in Internal Control over Financial Reporting
7 unchanged sentences
Other Information
+Added: Director and Officer Trading Arrangements
+Added: No officers or directors, as defined in Rule 16a-1(f), adopted or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement ,” as defined in Regulation S-K Item 408, during the last fiscal quarter.
Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
21 unchanged sentences
Amended and Restated Certificate of Incorporation of the Registrant.
−Removed: March 30, 2021
+Added: August 8, 2024
Amended and Restated Bylaws of the Registrant.
6 unchanged sentences
February 24, 2022
+Added: Form of Indenture
Form of Indemnification Agreement between the Registrant and each of its directors and executive officers.
8 unchanged sentences
February 23, 2023
+Added: 2024 Inducement Equity Incentive Plan and related forms of stock option and restricted stock unit agreements.
+Added: August 12, 2024
Offer Letter between the Registrant and Kevin Koch, Ph.D.
16 unchanged sentences
March 5, 2021
−Removed: Outside Director Compensation Policy.
+Added: Amended and Restated Outside Director Compensation Policy.
Form of Restricted Stock Unit Agreement .
−Removed: Sales Agreement, dated June 16, 2023, by and between the Registrant and BofA Securities, Inc .
−Removed: June 16, 2023
+Added: Stock Option Agreement between the Registrant and Dr.
+Added: Alan Russell, dated as of September 19, 2017.
+Added: November 7, 2024
+Added: Sales Agreement, dated May 10, 2024, by and between the Registrant and Leerink Partner LLC.
+Added: Offer Letter between the Registrant and Robert Blaustein, M.D., Ph.D.
+Added: Filed herewith
+Added: Insider Trading Policy
+Added: Filed herewith
Consent of Independent Registered Public Accounting Firm.
Filed herewith
−Removed: Power of Attorney (reference is made to the signature page hereto).
Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
6 unchanged sentences
Compensation Recovery Policy
−Removed: Filed herewith
+Added: February 22, 2024
XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
13 unchanged sentences
Indicates management contract or compensatory plan.
+Added: Portions of this exhibit have been redacted in compliance with Regulation S-K Ite 601(a)(6).
The certifications attached as Exhibit 32.1 that accompany this Annual Report on Form 10-K are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained in such filing.
1 unchanged sentence
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, duly authorized.
−Removed: February 22, 2024
+Added: March 3, 2025
EDGEWISE THERAPEUTICS, INC.
4 unchanged sentences
/s/ Kevin Koch
+Added: President, Chief Executive Officer and Director
+Added: March 3, 2025
Kevin Koch, Ph.D.
−Removed: President, Chief Executive Officer and Director (Principal Executive Officer)
−Removed: February 22, 2024
+Added: (Principal Executive Officer)
Michael Carruthers
+Added: Chief Financial Officer
+Added: March 3, 2025
Michael Carruthers
−Removed: Chief Financial Officer (Principal Financial and Accounting Officer)
−Removed: February 22, 2024
+Added: (Principal Financial and Accounting Officer)
/s/ Peter Thompson
−Removed: Peter Thompson, M.D.
Co-Founder, Chairman and Director
−Removed: February 22, 2024
+Added: March 3, 2025
+Added: Peter Thompson, M.D.
/s/ Alan Russell
−Removed: Alan Russell, Ph.D.
Chief Scientific Officer and Director
−Removed: February 22, 2024
+Added: March 3, 2025
+Added: Alan Russell, Ph.D.
/s/ Laura A.
−Removed: February 22, 2024
−Removed: H /s/ Badreddin Edris
−Removed: Badreddin Edris, Ph.D.
+Added: March 3, 2025
+Added: /s/ Badreddin Edris
Co-Founder and Director
−Removed: February 22, 2024
+Added: March 3, 2025
+Added: Badreddin Edris, Ph.D.
/s/ Jonathan Fox
+Added: March 3, 2025
Jonathan Fox, M.D., Ph.D., FACC
−Removed: February 22, 2024
+Added: /s/ Arlene Morris
+Added: March 3, 2025
+Added: Arlene Morris
/s/ Jonathan Root
+Added: March 3, 2025
Jonathan Root, M.D.
−Removed: February 22, 2024
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.